# CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

> **NCT07315087** · PHASE1 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 12 (estimated)

## Conditions studied

- SLE - Systemic Lupus Erythematosus
- SSc-Systemic Sclerosis
- IIM- Idiopathic Inflammatory Myopathies
- ANCA Associated Vasculitis (AAV)
- Connective Tissue Disease-Associated Thrombocytopenia
- SLE-ITP

## Interventions

- **BIOLOGICAL:** QT-019C

## Key facts

- **NCT ID:** NCT07315087
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-18
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07315087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07315087, "CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07315087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*